The deals add $135,000 in monthly recurring revenue, leverage a network of 1,500 online clinics and 350 facilities, and are intended to be non-dilutive to shareholders while accelerating Maxasome™ commercialization.
https://www.stocktitan.net/news/MAJI/nex-tel-...jxg.html